Quick Answer
Cadrenal Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $4.01 million for the year ending 2025.
- Cadrenal Therapeutics, Inc. showed a decrease of -60.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Cadrenal Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2023: $9.11 million | Q4 2023: $8.40 million | Q1 2024: $6.57 million | Q1 2025: $7.34 million | Q2 2025: $5.57 million | Q3 2025: $5.00 million | Q3 2025: $3.86 million.
- Over the full 4 years of available data (2022 to 2025), Cadrenal Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 12,199.1%.
- Historical annual values: Fiscal year 2025: $4.01 million | Fiscal year 2024: $10.02 million | Fiscal year 2023: $8.40 million | Fiscal year 2022: $32.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: